# EDGAR Filing Document

**Accession Number:** 0001860782
**File Stem:** 0001860782-23-000002
**Filing Date:** 2023-1
**Character Count:** 5234
**Document Hash:** 7fc981d7ea1af375174069977fbc8d39
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001860782-23-000002.hdr.sgml**: 20230105

**ACCESSION NUMBER**: 0001860782-23-000002

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20230104

**ITEM INFORMATION**: Other Events

**FILED AS OF DATE**: 20230105

**DATE AS OF CHANGE**: 20230105

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** 2seventy bio, Inc.
- **CENTRAL INDEX KEY:** 0001860782
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 863658454
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40791
- **FILM NUMBER:** 23511411

**BUSINESS ADDRESS:**
- **STREET 1:** 60 BINNEY STREET
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02210
- **BUSINESS PHONE:** 339-499-9300

**MAIL ADDRESS:**
- **STREET 1:** 60 BINNEY STREET
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02210

?xml version="1.0" ? tvst-20230104

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**__________________________**

**FORM 8-K**

**__________________________**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): January 4, 2023**

**__________________________**

**2seventy bio, Inc.**

**(Exact name of Registrant as Specified in Its Charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-40791** | **86-3658454** |
| **(State or other jurisdiction<br>of incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| **60 Binney Street,** | | **02142** |
| **Cambridge, MA** | | |
| **(Address of principal executive offices)** | | **(Zip Code)** |

---

**Registrant's telephone number, including area code: (339) 499-9300**

**Not Applicable**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, $0.0001 par value per share | TSVT | The NASDAQ Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ⌧

------

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

------

**Item 8.01&nbsp;&nbsp;&nbsp;&nbsp;Other Events.**

On January 4, 2023, the EBMT-EHA released an abstract previously submitted by 2seventy bio, Inc. (the "Registrant") [and Bristol Myers Squibb Company] for presentation at the EBMT-EHA 5th European CAR T-cell meeting. The abstract, available on the EBMT-EHA website, includes key data points from the positive results of the Registrant's KarMMa-3 study of ABECMA (idecabtagene vicleucel).

Results from KarMMa-3, a pivotal Phase 3, open-label, global, randomized, controlled study evaluating ABECMA (idecabtagene vicleucel) compared to standard combination regimens in adults with relapsed and refractory multiple myeloma after two to four prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody, and were refractory to their last regimen.

Ide-cel significantly improved progression-free survival versus standard regimens (median [95% CI] 13.3 [11.8-16.1] vs 4.4 [3.4-5.9] months; HR 0.49; 95% CI 0.38-0.65; P<0.0001). Overall response rate was significantly improved with ide-cel versus standard regimens (71% vs 42%; P<0.0001), with deeper, more durable responses.

Full results from the KarMMa-3 study will be presented at the EBMT-EHA 5th European CAR T-cell meeting, taking place from February 8-11, 2023, in Rotterdam, Netherlands.

____________

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Dated: January 5, 2023 | **2seventy bio, Inc.** | **2seventy bio, Inc.** |
|  | By: | /s/ Chip Baird |
|  |  | Chip Baird |
|  |  | Chief Financial Officer |
|  |  | (Principal Financial and Accounting Officer) |

---